See more : Nan Liu Enterprise Co., Ltd. (6504.TW) Income Statement Analysis – Financial Results
Complete financial analysis of MYUNGMOON Pharm co.,Ltd (017180.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MYUNGMOON Pharm co.,Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PKSHA Technology Inc. (3993.T) Income Statement Analysis – Financial Results
- Huagong Tech Company Limited (000988.SZ) Income Statement Analysis – Financial Results
- Diversified Healthcare Trust (DHCNL) Income Statement Analysis – Financial Results
- Safety Shot Inc (SHOT) Income Statement Analysis – Financial Results
- Rotork plc (ROR.L) Income Statement Analysis – Financial Results
MYUNGMOON Pharm co.,Ltd (017180.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mmpharm.co.kr
About MYUNGMOON Pharm co.,Ltd
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.57B | 152.13B | 137.76B | 127.85B | 149.35B | 147.50B | 140.14B | 142.18B | 125.10B | 105.42B | 103.72B | 100.54B | 125.62B | 105.18B | 97.19B | 77.39B | 60.93B |
| Cost of Revenue | 74.21B | 74.03B | 75.42B | 78.86B | 80.91B | 73.05B | 60.93B | 66.00B | 62.42B | 51.25B | 52.63B | 53.97B | 56.76B | 48.06B | 43.84B | 31.75B | 26.27B |
| Gross Profit | 95.35B | 78.10B | 62.34B | 48.99B | 68.43B | 74.45B | 79.20B | 76.18B | 62.68B | 54.17B | 51.09B | 46.57B | 68.86B | 57.12B | 53.35B | 45.64B | 34.66B |
| Gross Profit Ratio | 56.23% | 51.34% | 45.25% | 38.32% | 45.82% | 50.48% | 56.52% | 53.58% | 50.10% | 51.38% | 49.25% | 46.32% | 54.82% | 54.31% | 54.89% | 58.97% | 56.88% |
| Research & Development | 2.97B | 1.71B | 2.06B | 535.06M | 676.47M | 140.58M | 0.00 | 0.00 | 23.88M | 7.50M | 100.81M | 1.08B | 1.19B | 1.79B | 1.74B | 1.40B | 552.83M |
| General & Administrative | 4.18B | 4.67B | 3.88B | 13.96B | 14.70B | 13.55B | 13.74B | 12.29B | 12.65B | 8.92B | 9.78B | 11.26B | 11.67B | 8.79B | 8.70B | 6.00B | 4.26B |
| Selling & Marketing | 68.30B | 42.67B | 41.65B | 17.53B | 11.22B | 12.15B | 13.38B | 12.39B | 10.34B | 8.47B | 7.24B | 7.64B | 11.10B | 9.08B | 9.73B | 8.15B | 4.55B |
| SG&A | 72.48B | 47.33B | 45.53B | 31.49B | 25.92B | 25.69B | 27.11B | 24.67B | 22.99B | 17.39B | 17.02B | 18.90B | 22.76B | 17.87B | 18.43B | 14.16B | 8.81B |
| Other Expenses | 18.94B | 22.62B | 20.62B | 45.93B | 56.13B | 1.64B | 5.02B | 677.47M | -6.13B | 257.80M | 1.28B | 44.84M | 37.46M | -327.37M | -790.64M | -1.35B | -594.07M |
| Operating Expenses | 94.39B | 71.67B | 68.22B | 77.96B | 82.73B | 69.51B | 71.73B | 66.12B | 65.15B | 50.44B | 46.98B | 50.30B | 57.92B | 47.98B | 46.58B | 37.76B | 24.88B |
| Cost & Expenses | 168.60B | 145.70B | 143.64B | 156.82B | 163.64B | 142.56B | 132.66B | 132.12B | 127.57B | 101.69B | 99.62B | 104.26B | 114.67B | 96.05B | 90.42B | 69.51B | 51.16B |
| Interest Income | 223.58M | 150.80M | 172.76M | 200.33M | 145.81M | 152.54M | 225.64M | 158.55M | 287.34M | 215.66M | 199.98M | 160.85M | 354.24M | 502.31M | 382.86M | 213.09M | 157.82M |
| Interest Expense | 5.14B | 3.73B | 3.04B | 4.14B | 4.58B | 3.25B | 2.36B | 3.04B | 3.35B | 3.91B | 4.11B | 4.53B | 5.41B | 4.03B | 3.50B | 1.28B | 1.00B |
| Depreciation & Amortization | 4.17B | 4.18B | 3.76B | 3.80B | 3.66B | 1.91B | 1.98B | 2.00B | 2.02B | 2.31B | 2.26B | 2.25B | 2.28B | 3.09B | 3.42B | 2.42B | 1.33B |
| EBITDA | 4.53B | 10.57B | 345.37M | -19.35B | -10.94B | 7.06B | 14.45B | 13.23B | -5.08B | 6.03B | 6.36B | -2.71B | 13.52B | 12.61B | 10.10B | 9.55B | 10.95B |
| EBITDA Ratio | 2.67% | 7.07% | -0.18% | -18.06% | -5.78% | 5.87% | 10.50% | 9.10% | -5.01% | 6.20% | 7.54% | -1.29% | 10.80% | 12.13% | 10.43% | 12.31% | 17.84% |
| Operating Income | 963.77M | 6.43B | -5.88B | -28.96B | -14.29B | 4.94B | 7.47B | 10.06B | -2.47B | 3.73B | 4.11B | -3.72B | 10.76B | 9.14B | 6.77B | 7.88B | 9.77B |
| Operating Income Ratio | 0.57% | 4.23% | -4.27% | -22.65% | -9.57% | 3.35% | 5.33% | 7.07% | -1.97% | 3.53% | 3.96% | -3.70% | 8.57% | 8.69% | 6.96% | 10.18% | 16.04% |
| Total Other Income/Expenses | -5.75B | -3.78B | -717.32M | -4.15B | -4.89B | -3.04B | 2.63B | -4.30B | -7.98B | -3.04B | -3.00B | -5.77B | -4.93B | -3.64B | -3.60B | -2.03B | -1.16B |
| Income Before Tax | -4.78B | 2.65B | -6.60B | -27.29B | -19.18B | 1.89B | 10.11B | 8.19B | -10.45B | 686.36M | 1.10B | -9.49B | 5.83B | 5.50B | 3.17B | 5.85B | 8.62B |
| Income Before Tax Ratio | -2.82% | 1.74% | -4.79% | -21.35% | -12.85% | 1.28% | 7.21% | 5.76% | -8.36% | 0.65% | 1.06% | -9.44% | 4.64% | 5.23% | 3.26% | 7.55% | 14.14% |
| Income Tax Expense | 92.61M | -5.32B | 206.14M | 458.50M | 1.65B | 1.56B | 1.98B | 1.71B | 7.41B | 729.35M | 895.71M | 3.25B | 1.77B | 3.17B | 370.32M | 983.44M | 2.03B |
| Net Income | -4.52B | 7.87B | -6.80B | -27.75B | -20.83B | 988.27M | 7.81B | 6.75B | -16.14B | 761.49M | 1.03B | -12.27B | 4.55B | 3.07B | 2.94B | 4.86B | 6.58B |
| Net Income Ratio | -2.67% | 5.17% | -4.94% | -21.71% | -13.95% | 0.67% | 5.57% | 4.74% | -12.90% | 0.72% | 0.99% | -12.21% | 3.63% | 2.92% | 3.03% | 6.28% | 10.80% |
| EPS | -134.35 | 232.74 | -201.27 | -948.05 | -832.04 | 39.94 | 305.36 | 292.95 | -758.86 | 35.49 | 48.20 | -577.27 | 257.71 | 188.31 | 181.35 | 327.00 | 529.74 |
| EPS Diluted | -134.35 | 232.74 | -201.27 | -948.05 | -832.04 | 39.94 | 305.36 | 292.95 | -758.86 | 35.49 | 48.20 | -577.27 | 257.71 | 188.31 | 181.35 | 327.00 | 529.74 |
| Weighted Avg Shares Out | 33.68M | 33.81M | 33.81M | 29.27M | 25.04M | 24.74M | 25.57M | 22.31M | 21.26M | 21.45M | 21.29M | 21.26M | 17.66M | 16.29M | 16.22M | 14.87M | 12.43M |
| Weighted Avg Shares Out (Dil) | 33.68M | 33.81M | 33.81M | 29.27M | 25.04M | 24.74M | 25.57M | 23.03M | 21.26M | 21.45M | 21.29M | 21.26M | 17.66M | 16.29M | 16.22M | 14.87M | 12.43M |
Source: https://incomestatements.info
Category: Stock Reports